Search results
Traders Purchase Large Volume of Alnylam Pharmaceuticals Call Options (NASDAQ:ALNY)
ETF DAILY NEWS· 5 hours agoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) was the recipient of unusually large options trading activity on Monday. In related news, Director Amy W. Schulman sold 21,700 shares ...
Hereditary ATTR amyloidosis: Diagnosis & treatment
Medscape· 7 days agoAmyloid transthyretin (ATTR) amyloidosis comprises a group of rare and debilitating diseases of the adult that are characterized by the extracellular deposition of amyloid fibrils in tissues ...
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Zacks via Yahoo Finance· 3 days agoIntellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin...
Dianthus receives FDA greenlight to begin Phase II trial in MMN
Clinical Trials Arena via Yahoo Finance· 5 days agoDianthus says DNTH103 “holds the potential to be a pipeline in a product”, citing potential...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share
ETF DAILY NEWS· 4 days agoDianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Equities researchers at Lifesci Capital...
Sir Bill Browder: King’s birthday honour is for those killed for opposing Putin and those fighting...
The Independent via Yahoo News· 3 days agoExclusive: Human rights activist Bill Browder says his knighthood in the King’s Birthday Honours...
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase...
The Woonsocket Call· 2 days agoJohnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo ...
Alcohol Induced Epilepsy Seizures: Risks and Recommendations
Healthline· 6 days agoin people with epilepsy, especially in people with types of epilepsy that don’t respond well to...
FDA clears Dianthus Therapeutics' Phase 2 MMN drug trial By Investing.com
Investing.com· 5 days agoDianthus Therapeutics, Inc. (NASDAQ:DNTH), a biotech firm, has received FDA clearance for a Phase 2...
argenx’s (ARGX) “Buy” Rating Reaffirmed at HC Wainwright
ETF DAILY NEWS· 3 days agoHC Wainwright’s price objective would suggest a potential upside of 15.36% from the stock’s current price. Other research analysts have also issued research reports about the company. JMP Securities ...